Activity of cephalosporins against methicillin-susceptible and methicillin-resistant, coagulase-negative staphylococci: minimal effect of beta-lactamase.

Antimicrobial Agents and Chemotherapy
J F John, W F McNeill

Abstract

Eight cephalosporins were tested for their activity against methicillin-susceptible and methicillin-resistant, coagulase-negative staphylococci and for their resistance to beta-lactamase from methicillin-resistant, coagulase-negative staphylococci. Susceptibility testing by the agar plate method was evaluated for the effect of inoculum size and duration of incubation. Methicillin-susceptible, coagulase-negative staphylococci were highly susceptible to the cephalosporins, with cephapirin and cepahlothin showing the greatest activity, followed by cefazolin and cefamandole. Methicillin-resistant, coagulase-negative staphylococci displayed nearly total cross-resistance to the cephalosporins. Resistance increased with increasing inoculum size. Beta-Lactamases produced by methicillin-resistant, coagulase-negative staphylococci had a minimal hydrolytic effect on cepahlothin, cephapirin, cefazolin, and cefamandole and no measurable effect on cefoxitin. There was no correlation between the anti-staphylococcal activity and resistance to beta-lactamases.

References

Nov 1, 1978·Southern Medical Journal·W T SiebertT W Williams
Apr 1, 1978·Antimicrobial Agents and Chemotherapy·M LaverdiereL D Sabath
Mar 1, 1978·The Journal of Infectious Diseases·M LaverdiereL D Sabath
Jul 7, 1978·JAMA : the Journal of the American Medical Association·M A Parker, C U Tuazon
Jun 11, 1976·The Journal of Infectious Diseases·W E Farrar, P K Gramling
Aug 1, 1973·Archives of Internal Medicine·T F Keys, W L Hewitt
Aug 1, 1963·Proceedings of the Society for Experimental Biology and Medicine·J O KJELLANDERM FINLAND

❮ Previous
Next ❯

Citations

Oct 1, 1983·European Journal of Clinical Microbiology·A Tselenis-KotsowilisJ Papavassiliou
Mar 21, 1981·Lancet·C Marks, B H Cummins
Oct 1, 1986·Antimicrobial Agents and Chemotherapy·R J FassL W Ayers
Jan 1, 1987·Antimicrobial Agents and Chemotherapy·R E MenziesD MacCulloch
Nov 1, 1984·American Journal of Ophthalmology·J A KhanC H Ide
Jun 1, 1981·The Journal of Hospital Infection·M PapapetropoulosN J Legakis
Mar 1, 1986·The Journal of Hospital Infection·S Ponce de LeonR P Wenzel
Sep 1, 2005·The Journal of Bone and Joint Surgery. British Volume·M Al-MaiyahP J Gregg
Oct 1, 1985·Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. Section B, Microbiology·B G Hansen
Dec 1, 1986·Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. Section B, Microbiology·V T RosdahlA M Knudsen
Apr 1, 1985·Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. Section B, Microbiology·B G Hansen, K Rosendal
Dec 1, 1983·Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. Section B, Microbiology·B G Hansen
Sep 5, 1988·The Medical Journal of Australia·P McIntyreD Tudehope
Nov 1, 1982·Journal of Clinical Microbiology·C G Gemmell, J E Dawson

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.